Chapter 1 │ Page 26 19. Van den Eynde, A., et al., IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol, 2024. 17(1): p. 8. 20. Papa, S., et al., Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study. Journal for ImmunoTherapy of Cancer, 2023. 11(6): p. e007162. 21. Poudel, K., et al., Recent progress in cancer vaccines and nanovaccines. Biomaterials, 2025. 314: p. 122856. 22. de Sousa, L.G. and R. Ferrarotto, Pembrolizumab in the first-line treatment of advanced head and neck cancer. Expert Rev Anticancer Ther, 2021. 21(12): p. 1321-1331. 23. Baas, P., et al., First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet, 2021. 397(10272): p. 375-386. 24. Shiravand, Y., et al., Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol, 2022. 29(5): p. 3044-3060. 25. Spigel, D.R., et al., ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). Journal of Clinical Oncology, 2024. 42(17_suppl): p. LBA5-LBA5. 26. Lin, X., et al., Regulatory mechanisms of PD-1/PD-L1 in cancers. Molecular Cancer, 2024. 23(1): p. 108. 27. Keilholz, U., CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother, 2008. 31(5): p. 431-9. 28. Callejas-Valera, J.L., et al. Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. Cancers, 2022. 14, DOI: 10.3390/cancers14102499. 29. Passaro, A., et al., Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. Journal of Clinical Oncology, 2022. 40(6): p. 598-610. 30. Dos Santos, L.V., C.M. Abrahão, and W.N. William, Jr., Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas. Front Oncol, 2021. 11: p. 596290. 31. Schoenfeld, A.J. and M.D. Hellmann, Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell, 2020. 37(4): p. 443-455. 32. Yin, Q., et al., Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol, 2023. 14: p. 1167975. 33. Klein-Brill, A., et al., Comparative e icacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study. BJC Reports, 2024. 2(1): p. 14. 34. Aggarwal, V., C.J. Workman, and D.A.A. Vignali, LAG-3 as the third checkpoint inhibitor. Nature Immunology, 2023. 24(9): p. 1415-1422. 35. Tawbi, H.A., et al., Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine, 2022. 386(1): p. 24-34. 36. Wang, J.-C., et al., VISTA Is the Predominant 2nd Generation of ICI (Immune CheckPoint Inhibitor) in Ph(-) myeloproliferative Neoplasm. Blood, 2023. 142(Supplement 1): p. 6351-6351.
RkJQdWJsaXNoZXIy MTk4NDMw